BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 7, 2012, Pages 631-639

  Ida, Cristiane M ^a   Lambert, Sally R ^c   Rodriguez, Fausto J ^b   Voss, Jesse S ^a   Mc Cann, Brooke E ^a   Seys, Amber R ^a   Halling, Kevin C ^a   Collins, V Peter ^c   Giannini, Caterina ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BRAF; Cerebellar astrocytoma; Diffuse; IDH1; IDH2; Low grade; Pilocytic

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; CEREBELLUM TUMOR; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE ASTROCYTOMA; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; PILOCYTIC ASTROCYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ASTROCYTOMA; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862840727     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31825c448a     Document Type: Article

References (47)

1. Hayostek CJ, Shaw EG, Scheithauer B, et al. Astrocytomas of the cerebellum. A comparative clinicopathologic study of pilocytic and diffuse astrocytomas. Cancer 1993;72:856-69 (Pubitemid 23215276)
2. Palma L, Russo A, Celli P. Prognosis of the so-called "diffuse" cerebellar astrocytoma. Neurosurgery 1984;15:315-7 (Pubitemid 14029944)
3. Scheithauer BW, Hawkins C, Tihan T, et al. Pilocytic astrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, et al, eds. WHO Classification of Tumours of the Central Nervous System World Health Organization Classification of Tumours. Lyon, France: International Agency for Research on Cancer, 2007:14-21
4. Rodriguez FJ, Perry A, Gutmann DH, et al. Gliomas in neurofibromatosis type 1: A clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67:240-49 (Pubitemid 351483292)
5. WHO Classification of Tumors of the Central Nervous System. 4th ed. Lyon, France: International Agency for Research on Cancer, 2007
6. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
7. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602
8. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341-47
9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
10. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469-74
11. Pusch S, Sahm F, Meyer J, et al. Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 2011;37:428-30
12. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44
13. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27: 5874-80
14. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16: 1597-604
15. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-54
16. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-53
17. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118:1739-49 (Pubitemid 351632377)
18. Yu J, Deshmukh H, Gutmann RJ, et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009;73: 1526-31
19. Schiffman JD, Hodgson JG, VandenBerg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010;70:512-19
20. Lawson AR, Tatevossian RG, Phipps KP, et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol 2010;120:271-73
21. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673-77
22. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 2009;19:449-58
23. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009;218:172-81
24. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011;121:763-74
25. Tatevossian RG, Lawson AR, Forshew T, et al. MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010;222:509-14
26. Tian Y, Rich BE, Vena N, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 2011;13:669-77
27. Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549: BRAF fusion variants. J Neuropathol Exp Neurol 2012;71:66-72
28. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405
29. Eisenhardt AE, Olbrich H, Roring M, et al. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2010;129:2297-2303
30. Jones DT, Kocialkowski S, Liu L, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28:2119-23
31. Sharma MK, Zehnbauer BA, Watson MA, et al. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005;65:1335-36 (Pubitemid 41508250)
32. Janzarik WG, Kratz CP, Loges NT, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007;38: 61-63 (Pubitemid 47434497)
33. Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60:917-20 (Pubitemid 32880599)
34. Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000;59: 759-67
35. Gutmann DH, Donahoe J, Brown T, et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000;26:361-67 (Pubitemid 30609432)
36. Horbinski C, Hamilton RL, Nikiforov Y, et al. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641-49
37. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009;118:401-5
38. Bar EE, Lin A, Tihan T, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 2008;67:878-87
39. Nakamura N, Carney JA, Jin L, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest 2005;85: 1065-75 (Pubitemid 43073981)
40. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15: 136-43 (Pubitemid 44325474)
41. Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic astrocytomas in children: prognostic factorsVa retrospective study of 80 cases. Neurosurgery 2003;53:544-53; discussion 54-55
42. Fisher PG, Tihan T, Goldthwaite PT, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008;51:245-50 (Pubitemid 351874420)
43. Koeller KK, Rushing EJ. From the archives of the AFIP: Pilocytic astrocytoma: Radiologic-pathologic correlation. Radiographics 2004;24: 1693-708
44. Jones DT, Mulholland SA, Pearson DM, et al. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathol 2011;121:753-61
45. von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011;21:74-87
46. Hayden JT, Fruhwald MC, Hasselblatt M, et al. Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 2009;8:1806-7
47. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS One 2011;6:e17948